{Reference Type}: Case Reports
{Title}: Rare ROS1-CENPW gene in pancreatic acinar cell carcinoma and the effect of crizotinib plus AG chemotherapy: A case report.
{Author}: Wang T;Shen YY;
{Journal}: World J Clin Cases
{Volume}: 11
{Issue}: 24
{Year}: 2023 Aug 26
{Factor}: 1.534
{DOI}: 10.12998/wjcc.v11.i24.5823
{Abstract}: <B>BACKGROUND: </B>This is the first report of an ROS1-CENPW fusion gene in pancreatic malignancies.<BR><B>METHODS: </B>A 77-year-old woman with a pancreatic tumor and multiple liver metastases was admitted to our hospital. Genetic testing revealed the presence of the ROS1-CENPW fusion gene, a rare fusion gene that has not been previously reported in the field of pancreatic cancer. The patient received crizotinib plus AG (albumin paclitaxel plus gemcitabine) chemotherapy. After treatment, the patient's condition stabilized, and her prognosis was good.<BR><B>CONCLUSIONS: </B>The ROS1-CENPW gene treatment regimen used in this case is an excellent treatment option that provides new hope for patients with advanced pancreatic cancer and similar genetic mutations. To date, owing to the rarity of the ROS1-CENPW fusion gene, our team has encountered only a single case. Therefore, the efficacy of crizotinib plus AG chemotherapy in patients with pancreatic acinar cell carcinoma harboring the ROS1-CENPW fusion gene requires further validation.